← Back to Clinical Trials
Recruiting NCT04949282
Spanish Series of Patients Treated With the Radionuclide Lutetium177
Trial Parameters
Condition Neuroendocrine Tumors
Sponsor Sociedad Española de Medicina Nuclear e Imagen Molecular
Study Type OBSERVATIONAL
Phase N/A
Enrollment 5,000
Sex ALL
Min Age 18 Years
Max Age 100 Years
Start Date 2021-05-10
Completion 2034-12-31
All Conditions
Neuroendocrine Tumors Intestinal Neoplasms Pancreatic Neoplasms Stomach Neoplasms Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Nerve Tissue Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Endocrine Gland Neoplasms Digestive System Diseases Gastrointestinal Disease Intestinal Diseases Pancreatic Disease Endocrine System Diseases
Interventions
Lutetium [177Lu] oxodotreotide/dotatateLutetium [177Lu] oxodotreotide/dotatate
Brief Summary
This study aims to pool the clinical experience of Spanish centers treating patients with 177Lu-DOTATATE to evaluate the efficacy, tolerance, and safety of the drug in routine clinical practice and to learn about the profiles of patients and tumors treated and the results in each type of patient and tumor.
Eligibility Criteria
Inclusion Criteria: * Written informed consent must be obtained prior to any data collection. * Patients must be diagnosed with unresectable or metastatic, progressive, somatostatin receptor positive tumour * Aged ≥18 years. Exclusion Criteria: * None
Related Trials
NCT04888481
68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors
View Trial →
NCT04949282
Spanish Series of Patients Treated With the Radionuclide Lutetium177
View Trial →
NCT05804331
The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study
View Trial →